Skip to main content

Coagulation Disorder

3
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

VarmX
VarmXNetherlands - Leiden
3 programs
3
VMX-C001Phase 11 trial
VMX-C001Phase 11 trial
VMX-C001Phase 11 trial
Active Trials
NCT06372483Active Not Recruiting40Est. Aug 2026
NCT05152420Completed105Est. Feb 2023
NCT06517563Active Not Recruiting16Est. Oct 2026
Takeda
TakedaTOKYO, Japan
1 program
TAK-330PHASE_31 trial
Active Trials
NCT05156983Recruiting328Est. Apr 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
TakedaTAK-330
VarmXVMX-C001
VarmXVMX-C001
VarmXVMX-C001

Clinical Trials (4)

Total enrollment: 489 patients across 4 trials

NCT05156983TakedaTAK-330

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Start: Aug 2022Est. completion: Apr 2028328 patients
Phase 3Recruiting
NCT06517563VarmXVMX-C001

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Start: Aug 2024Est. completion: Oct 202616 patients
Phase 1Active Not Recruiting
NCT06372483VarmXVMX-C001

Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

Start: Feb 2024Est. completion: Aug 202640 patients
Phase 1Active Not Recruiting
NCT05152420VarmXVMX-C001

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Start: Oct 2021Est. completion: Feb 2023105 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 489 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.